One of the reasons for the lack of efficacy when performing such a combination is that HCC behaves in a “BCL-xL-dependent tumor,” according to Tutusaus et al. In fact, testing such combination might be of most important because it may overcome sorafenib resistance. This evidence concerns the gene BCL2L1 and neoplasm.